JPRN-UMIN000020543已完成未知
Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis - Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis
ational Hospital Organization Okayama Medical Center0 个研究点目标入组 8 人开始时间: 2016年1月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with a contraindication to imatinib Patients who were considered as inadequate for enrollment by the principal investigator
研究者
相似试验
招募中
不适用
Effects of nintedanib in idiopathic pulmonary fibrosis - analysis on long term prognosis and predictive factorsIdiopathic pulmonary fibrosisJPRN-UMIN000021036ational Hospital Organization Tokyo Medical Center, Department of Respiratory Medicine100
招募中
1 期
Safety and efficacy of imatinib therapy administered in patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM) : A prospective studyPatients with malignancy, suspected of Pulmonary Tumor Thrombotic Microangiopathy (PTTM)JPRN-jRCTs031210263Hatano Masaru20
已完成
2 期
COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in Covid19 * a randomized, double-blind, placebo controlled, clinical trial in patients with severe Covid19 diseasePulmonary edemaCOVID-19 disease10024970NL-OMON49996Vrije Universiteit Medisch Centrum386
进行中（未招募）
1 期
Countering Lung Damage in COVID-19 infection: the CounterCovid StudyEUCTR2020-001236-10-NLAmsterdam UMC386
进行中（未招募）
1 期
Countering Lung Damage in COVID-19 infection: the CounterCovid StudyCovid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease.EUCTR2020-001236-10-BEAmsterdam UMC385